Compare EH & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EH | FTRE |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.8M | 829.3M |
| IPO Year | 2019 | 2023 |
| Metric | EH | FTRE |
|---|---|---|
| Price | $9.88 | $10.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $22.47 | $14.06 |
| AVG Volume (30 Days) | 505.1K | ★ 946.1K |
| Earning Date | 05-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $33.23 | N/A |
| Revenue Next Year | $73.83 | $3.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $9.06 | $3.97 |
| 52 Week High | $20.44 | $18.67 |
| Indicator | EH | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 57.98 |
| Support Level | $9.06 | $8.80 |
| Resistance Level | $11.94 | $11.59 |
| Average True Range (ATR) | 0.41 | 0.61 |
| MACD | -0.09 | 0.13 |
| Stochastic Oscillator | 4.41 | 83.70 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.